Stereotactic Body Radiotherapy for Prostate Cancer
Prostate cancer remains the most common and second most deadly cancer diagnosed amongst U.S. men. External beam radiotherapy is a standard-of-care definitive treatment option for localized prostate cancer and historically constituted an 8–9-week treatment course comprised of 39–45 doses of 1.8–2.0 G...
Main Authors: | Neil R. Parikh M.D., Amar U. Kishan M.D. |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-06-01
|
Series: | American Journal of Men's Health |
Online Access: | https://doi.org/10.1177/1557988320927241 |
Similar Items
-
Ablative Radiotherapy in Prostate Cancer: Stereotactic Body Radiotherapy and High Dose Rate Brachytherapy
by: Ting Martin Ma, et al.
Published: (2020-12-01) -
Clinical Assessment of Prostate Displacement and Planning Target Volume Margins for Stereotactic Body Radiotherapy of Prostate Cancer
by: Rebecca Levin-Epstein, et al.
Published: (2020-04-01) -
Treatment Interruptions During Stereotactic Body Radiotherapy for Prostate Cancer
by: Aghdam, N., et al.
Published: (2022) -
Stereotactic body radiotherapy for organ-confined prostate cancer
by: Diblasio Ferdinand, et al.
Published: (2010-02-01) -
Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial
by: Ting Martin Ma, et al.
Published: (2021-05-01)